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ORIGINAL ARTICLE
Pattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit
Emad Uddin Siddiqui,1 Sayyeda Ghazala Kazi,2 Muhammad Irfan Habib,3 Khalid Mehmood Ahmed Khan,4 Nukhba Zia5

Abstract
Objective: To determine the frequency, site and time to relapse from diagnosis, and to see the relationship of
relapse with important prognostic factors.
Methods: The prospective descriptive observational study was conducted at the National Institute of Child Health,
Karachi, June 2005 to May 2007, and comprised newly-diagnosed cases of acute lymphoblastic leukaemia. Bone
marrow aspiration was done on reappearance of blast cells in peripheral smear and cerebrospinal fluid. Detailed
report was done each time when intra-thecal chemotherapy was given or there were signs and symptoms
suggestive of central nervous system relapse. SPSS 12 was used for data analysis.
Results: Of the 60 patients enrolled, 4(6.6%) expired and 1(1.7%) was lost to follow-up. Of the 55(91.6%) who
comprised the study sample, 35(58%) were males and 25(42%) females. Mean age of relapse was 6.8±3.27 years.
Mean time to relapse from diagnosis was 1.3±0.54 years; 12(20%) patients suffered relapse, and of them 5(14%) were
boys. Central nervous system relapse in 8(67%) patients was the most common site, with 3(25%) bone-marrow
relapses. Out of 12 patient with relapses, 9(75%) had white blood cell count less than 50,000/cm.
Conclusion: Relapse in acute lymphoblastic leukaemia was common, although treatment modalities are improving day by day.
Keywords: Acute lymphoblastic leukaemia, Blast cells, Bone marrow, Relapse. (JPMA 66: 961; 2016)

Introduction
Paediatric acute lymphoblastic leukaemia (ALL) is a
biologically heterogeneous disease and is the most
common childhood malignancy in most parts of the world.
It represents approximately 30% of all malignancies in
children younger than 15 years.1-6 Moreover, it constitutes
32% of all paediatric cancers4 and is the 5th most common
paediatric malignancy, with more than 3,000 new cases in
the United States annually.5-10 The incidence of ALL is
approximately 3-4/100,000 among under 15-year-olds.3
ALL, is a malignant disorder of blood in which lymphoblast,
an early precursor of lymphoid series, replaces the normal
haematopoietic cells of bone marrow (BM). This results in
decreased production of normal cells leading to anaemia,
thrombocytopenia and neutropenia of varying degrees.
Traditionally, its treatment is based on induction, remission,
consolidation phase, followed by maintenance therapy and
the prophylaxis. With the advent of modern combination
chemotherapy, along with effective central nervous system
(CNS) prophylaxis and risk adaptive treatment protocol,
survival outcome has dramatically improved to over 80% in
developed countries.3-6 However, relapse is still observed in
15-20% of children during or even after completion of therapy.
BM relapse is the major obstacle to cure in 10-15% of young
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patients. The most important determinant of outcome is the
duration of initial remission and site of relapse.6 ALL may also
relapse in unusual extramedullary sites like bones and joints.8
The rate of clearing the leukemic cells from the smear after the
initiation of therapy is associated with the outcome, gender
(especially female), age (1-9 years), that have favourable
outcome. Higher white blood cell (WBC) count at the time of
diagnosis may have an increased risk of treatment failure and
relapse with B-precursor ALL. Elevated WBC count is also
associated with other prognostic factors such as unfavourable
chromosome translocations like t (4:11) and t (9:22).
In most patients, the disease ultimately recurs. It is thought
that such relapses result from a sub-clinical level of residual
leukaemia known as minimal residual disease (MRD).9
MRD-based high-risk patients have a significantly greater
rate of relapse than the low-risk group. MRD detection can
help in using more intensive therapy for patients who are at
true risk of relapse.10 After initial intensive chemotherapy,
MRD detection is done by several methods. Literature
shows that patients with MRD at the end of induction have
progressed almost as poorly as those with >5% marrow
blast cells i.e. treatment failure.11 It has been identified by
various studies that children with negative blood MRD by
8th day of induction had excellent prognosis while those
whose BM MRD was positive by 29th day (end of induction)
had high rates of relapse. Current clinical trials for children
with leukaemia now incorporate MRD monitoring at the
end of induction into risk stratification for additional
therapy and are evaluating the sensitivity and specificity of
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MRD in predicting later relapse.12
The current study was planned to identify the relationship
of relapse in ALL with age and gender as well as WBC
count at the time of diagnosis. Besides, identification of
the site of relapse was also explored and so was time to
relapse after initiation of therapy.

Patients and Methods
The prospective descriptive observational study was
conducted at the Oncology Unit of the National Institute of
Child Health (NICH), Karachi, from June 2005 to May 2007.
After ethical approval from the institutional review board,
all newly-diagnosed cases of ALL on the basis of blast cells
on peripheral smear or immunophenotyping, between 214 years of age and of either gender, were enrolled.
Patients with other malignancies and those who had
received initial treatment somewhere else were excluded.
Patients who fulfilled the inclusion criteria were selected for
follow-up after obtaining verbal informed consent from their
parents. The follow-up lasted three years, and was taken as
standard for the NICH to assess the early complication or
relapse.The follow-up started with the consolidation phase and
continued after the completion of ALL treatment for two years.
United Kingdom ALL (UKALL) protocol 2003 v 7 and BerlinFrankfurt-Munster (BFM) protocol was used to treat the study
group.13,14 The said institution was using both protocols to treat
ALL as per the clinic-pathological situation of the patients. Most
of the information was taken from patients' files. During
chemotherapy, BM aspiration was performed on day 1 and
then on day 28. Thereafter BM aspiration was done only if
complete blood count (CBC) showed reappearance of blast
cells. Cerebrospinal Fluid detailed report (CSF D/R) for blast cells
was performed each time when intrathecal chemotherapy was
given, that is on days 1, 15 and 28 of induction phase and then
in weeks 8, 9, 10, 11 and 16 during interim maintenance phase,
or in the presence of signs and symptoms suggestive of CNS
relapse. In the absence of any evidence, no testicular
ultrasound and biopsy were performed.
SPSS 12 was used to analyse the data. Frequencies and
percentages were calculated for all qualitative/categorical
variables including gender, age groups, and relapse in
patients. Mean and standard deviation (SD) were
computed for age and time to relapse. Chi-square test of
independence was used to see the association of age
groups and gender with relapse (positive or negative), at
5% level of significance. A Kaplan-Meier method and logrank test was used to see the difference in survival curves
and estimation of survival over time.

Results
Of 60 patients enrolled, 04(6.6%) patients died and
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Table-1: Demography and Laboratorial data.
n (%)
Gender
Male
Female
Total
Age group
2-5 years
6-9 years
10-14 years
Total
LFT
Normal
De-ranged
Total
HBsAG
+ve
-ve
Total
Coagulation screen
Normal
De-ranged
Total
Hyperuricaemia
Yes
No
Total
Urea and Creatinine
Normal
De-ranged
Total
Tumour lysis
Yes
No
Total
CSF blast
+ve
-ve
Total
Treatment
BFM
UKALL
Total
Relapses
No
Yes
Total
Site relapse
Bone Marrow
CNS
Combine
Total

35 (58.3)
25 (41.7)
60
34 (56.7)
13 (21.7)
13 (21.7)
60
56 (93.3)
4 (6.7)
60
2 (3.3)
58 (96.7)
60
57 (95)
3 (5)
60
11 (18.3)
49 (81.7)
60
58 (96.7)
2 (3.3)
60
1 (1.7)
59 (98.3)
60
4 (6.7)
56 (93.3)
60
28 (46.7)
32 (53.3)
60
48 (80.0)
12 (20.0)
60
3 (25.0)
8 (66.7)
1 (8.3)
12

LFT: Liver function test. HBsAG: Hepatitis B surface antigen.
CSF: Cerebrospinal fluid.
BFM: Berlin-Frankfurt-Munster.
UKALL: United Kingdom Acute Lymphoblastic Leukaemia.
CNS: Central nervous system.
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Figure: Different Kaplan-Meier survival plots showing
probability of survival with time to relapse (in months).
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Table-2: Percent of relapses by different associated factors.

Gender
Male
Female
N
Treatment
BFM
UKALL
N
Age Group
2-5 years
6-14 years
N
WBC counts
> 50,000
<= 50,000
N
LFT
Normal
De-ranged
N
HBsAG
+ve
-ve
N
Coagulation Screen
Normal
De-ranged
N
Hyperuricemia
Yes
No
N
Urea n Creatinine
Normal
De-ranged
N
Tumour lysis
Yes
No
N
CSF blast
+ve
-ve
N

No-relapse N=48

Relapse N=12

Total N=60

P-value

30 (85.7)
18 (72)
48

5 (14.3)
7 (28)
12

35
25
60

0.210

22 (78.6)
26 (81.3)
48

6 (21.4)
6 (18.8)
12

28
32
60

1.00

27 (79.4)
21 (80.8)
48

7 (20.6)
5 (19.2)
12

34
26
60

1.00

15 (83.3)
33 (78.6)
48

3 (16.7)
9 (21.4)
12

18
42
60

1.00

46 (82.1)
2 (50)
48

10 (17.9)
2 (50)
12

56
4
60

0.175

1 (50)
47 (81)
48

1 (50)
11 (19)
12

2
58
60

0.363

46 (80.7)
2 (66.7)
48

11 (19.3)
1 (33.3)
12

57
3
60

0.495

7 (63.6)
41 (83.7)
48

4 (36.4)
8 (16.3)
12

11
49
60

0.206

47 (81)
1 (50)
48

11 (19)
1 (50)
12

58
2
60

0.363

0 (0)
48 (81.4)
48

1 (100)
11 (18.6)
12

1
59
60

0.200

3 (75)
45 (80.4)
48

1 (25)
11 (19.6)
12

4
56
60

1.00

BFM: Berlin-Frankfurt-Munster
UKALL: United Kingdom Acute Lymphoblastic Leukaemia
WBC: White blood cell
HBsAG: Hepatitis B surface antigen
CSF: Cerebrospinal fluid.

01(1.7%) was lost to follow-up. Of the 55(91.6%)
patients, in the study, 35(58%) were boys and 25(42%)
were girls; the male-to-female ratio being 1.4:1 (Table1). Mean age was 6.8±3.27 years, whereas mean time to

relapse from diagnosis was 1.3±0.54 years. There were
12(20%) cases of relapse; 7(59%) were between 2-5
years of age, 4(33%) between 6-9 years and 1(8%) was
over 10 years.
J Pak Med Assoc
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Table-3: Per cent of background characteristics by type of treatment.

Gender
Male
Female
N
Age Group
2-5 years
6-14 years
N
WBC counts
> 50,000
<= 50,000
N

BFM N=28

UKALL N=32

Total N=60

P-value

14 (50)
14 (50)
28

21 (65.6)
11 (34.4)
32

35
25
60

0.221

12 (42.9)
16 (57.1)
28

22 (68.8)
10 (31.3)
32

34
26
60

0.04

18 (64.3)
10 (35.7)
28

0 (0)
32 (100)
32

18
42
60

<0.0001

WBC: White blood cell.

Table-4: Kaplan Meier analysis for comparison of mean survival time between two groups.

Treatment
BFM
UKALL
Gender
Male
Female
WBC counts
> 50,000
<= 50,000
Age Group
2-5 years
6-14 years
Over all

Mean

S.E

N

95% Confidence Interval

P-value

31.6
32.3

2.1
1.4

28
32

(27.4, 35.8)
(29.5, 35.1)

0.658

32.5
31.1

1.5
2.1

35
25

(29.6, 35.4)
(27.0, 35.3)

0.122

30.5
32.6

2.9
1.3

18
42

(24.8, 36.1)
(30.0, 35.1)

0.987

32.6
31.3
32.0

1.5
2.0
1.237

34
26
60

(29.6, 35.6)
(27.4, 35.2)
(29.6, 34.4)

0.898

BFM: Berlin-Frankfurt-Munster.
UKALL: United Kingdom Acute Lymphoblastic Leukaemia.
WBC: White blood cell.

Among the case with relapse, 3(25%) had it within a year,
while 9(75%) had relapse within two years. The mean time
to relapse was 17.4±10.2 months.
The association of relapsed and non-relapsed
patients with demography and laboratory factors
were not statistically significant ( Table-2). The
treatment mode with gender and WBC count showed
significant 95% confidence interval (CI) (Table-3). The
mean survival time calculated was 32±1.23 months
(95% CI: 29.6, 34.4) with probability of survival at 80%
(Figure). Younger age group, females, and those with
platelets count <50,000 had better survival outcomes
( Table 4). But we did not find any significant
difference between UKALL and BFM protocols
(p>0.05).
Vol. 66, No. 8, August 2016

Discussion
ALL is common in children aged 2-5 years. Our study
demonstrated male predominance with ALL, but no
significant difference could be identified among different
age groups with fewer relapse rates. Both the treatment
protocols had similar outcomes for cure and relapse. All
patients had relapse while on different phases of
chemotherapy.
ALL survival among children has improved to
approximately 80%,15 but the outcome for those who
have a relapse remains poor.16,17 This study gives us an
insight into the patterns of relapse in children with ALL.
Four successive Medical Research Council-ALL trials
during 1985 and 2001 identified that the overall incidence
of relapse has decreased to 49%,18 though incidence and
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pattern of relapses may vary according to the protocols
used.
The pattern of relapse in childhood ALL has changed with
respect to time and site.
Irrespective of treatment protocols, relapses in paediatric
population is dependent on the duration of initial
remission,17 followed by predilection for extra-medullary
relapses, especially CNS. Those who relapse within the
first 18 months of diagnosis also have significantly worse
outcome.
Organ of relapse is the crucial predictor for second
remission, event-free survival, and overall survival after
relapse.19 The rates of isolated meningeal and testicular
relapses have now been reduced to 5% and <1%,
respectively. However the BM still remains the major site
of relapse which is in contrast to CNS relapse observed in
our study.
Rivera GP et al,20 demonstrated a reduction of 10%
relapse rate with intensive and timely first-line treatment.
Similarly, an Indian study identified 29.9% relapse after
complete remission of disease with BM as the most
frequent site; most (73%) were receiving chemotherapy
when the relapse occurred or they had it within 6 months
of the therapy completion.21 Relapse while on
chemotherapy and high incidence of CNS and testicular
relapse indicate the need for reappraisal of treatment
protocols.22
ALL can relapse even after decades; two- or three-year
follow-ups are too short to ascertain the types and site of
relapses. However this may help to distinguish the pattern
of early relapse while on chemotherapy or shortly after.
We found no big difference between short- and long-term
follow-ups. Huang et al. followed ALL over a period of 15
years and found 31% relapse.23 Schmiegelow et al. found
65% BM relapse and 22% CNS relapse with 10% relapse in
testes over a period of 21 years of follow-up.24 Further,
27% of relapses were observed in the study of Children's
Cancer and Leukaemia Study Group from 1981 to 1988
with BM at 70%, CNS 25% and testes 5%.25 Isolated
relapses of marrow and the CNS as documented by
Kulkarni et al.22 were different from this study. Similarly,
multivariate regression analysis showed that gender and
total leukocyte count (TLC) were significant predictors of
relapse.
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diagnosis.26 However, Horibe et al. identified female
gender, B-cell precursor ALL and WBC count as favourable
prognostic factors for ALL in children.27 However,
univariate analysis by Donadieu et al. described male,
initial WBC count of 50,000/cm3 and age under one and
more than 9 years as predictive of poor outcome.28 But
Paediatric Oncology Group Study demonstrated no
difference in gender and outcome analysis.29
According to another study conducted at National Taiwan
University Hospital for newly-diagnosed cases of
childhood ALL, univariate analysis of failure-free survival
showed six variables with significant detrimental effects
on eventual outcome, including high TLC (greater than
50,000/cm3).30

Conclusion
Relapse in ALL is common though treatment modalities
are improving day by day. CNS relapse was more
common, with higher rates among girls. Most patients
relapsed during maintenance therapy so there is a need
to introduce a more intensive maintenance therapy. To
reduce the frequency of relapse, efforts should be done
for early detection of high-risk patients.
Disclosure: No.
Conflict of Interest: No.
Funding Sources: No.
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